India Drug Manufacturers Stock News
Categories
- All
- Editor's Picks
- Stock Market News
- Q&A with Gurus
- Gurus' Stock Picks
- Insider Transaction
- Earning Reports
- CEO Shareholder Letters
- Press Release
- Earnings Call Transcripts
- Instant Alerts
- Podcast
Industries
- Aerospace & Defense
- Agriculture
- Asset Management
- Banks
- Beverages - Alcoholic
- Beverages - Non-Alcoholic
- Biotechnology
- Building Materials
- Business Services
- Capital Markets
- Chemicals
- Conglomerates
- Construction
- Consumer Packaged Goods
- Credit Services
- Diversified Financial Services
- Drug Manufacturers
- Education
- Farm & Heavy Construction Machinery
- Forest Products
- Furnishings, Fixtures & Appliances
- Hardware
- Healthcare Plans
- Healthcare Providers & Services
- Homebuilding & Construction
- Industrial Distribution
- Industrial Products
- Insurance
- Interactive Media
- Manufacturing - Apparel & Accessories
- Media - Diversified
- Medical Devices & Instruments
- Medical Diagnostics & Research
- Medical Distribution
- Metals & Mining
- Oil & Gas
- Other Energy Sources
- Packaging & Containers
- Personal Services
- Real Estate
- REITs
- Restaurants
- Retail - Cyclical
- Retail - Defensive
- Semiconductors
- Software
- Steel
- Telecommunication Services
- Tobacco Products
- Transportation
- Travel & Leisure
- Utilities - Independent Power Producers
- Utilities - Regulated
- Vehicles & Parts
- Waste Management
Drug Manufacturers
IOL Chemicals And Pharmaceuticals Ltd (BOM:524164) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Expansion and Diversification
Despite a dip in profitability, IOL Chemicals And Pharmaceuticals Ltd (BOM:524164) focuses on growth through new facilities and increased export revenues. Nov 20, 2024
Drug Manufacturers
Q2 2025 IOL Chemicals and Pharmaceuticals Ltd Earnings Call Transcript
Nov 20, 2024
Drug Manufacturers
Gufic Biosciences Ltd (BOM:509079) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges and Strategic Expansions
Despite a dip in quarterly revenue, Gufic Biosciences Ltd (BOM:509079) focuses on strategic growth with new facilities and international market expansions. Nov 19, 2024
Drug Manufacturers
Shilpa Medicare Ltd (BOM:530549) Q2 FY25 Earnings Call Highlights: Strong Formulations Drive Revenue Growth Amid API Challenges
Shilpa Medicare Ltd (BOM:530549) reports robust revenue and EBITDA growth, while addressing challenges in the API segment and high tax rates. Nov 15, 2024
Drug Manufacturers
Ipca Laboratories Ltd (BOM:524494) Q2 2025 Earnings Call Highlights: Strong Growth in Domestic and Export Formulations
Ipca Laboratories Ltd (BOM:524494) reports robust growth in key segments, despite challenges in branded promotional and API businesses. Nov 15, 2024
Drug Manufacturers
Sequent Scientific Ltd (BOM:512529) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Merger Impact
Sequent Scientific Ltd (BOM:512529) reports robust revenue growth and transformative merger benefits, despite challenges in API revenues and geopolitical risks. Nov 15, 2024
Drug Manufacturers
Marksans Pharma Ltd (BOM:524404) Q2 FY25 Earnings Call Highlights: Strong Revenue Growth and Strategic Market Expansion
Marksans Pharma Ltd (BOM:524404) reports impressive revenue growth driven by new product launches and market share gains, despite challenges in the UK and Europe. Nov 14, 2024
Drug Manufacturers
Alkem Laboratories Ltd (BOM:539523) Q2 2025 Earnings Call Highlights: Strong Net Profit Growth Amidst US Market Challenges
Alkem Laboratories Ltd (BOM:539523) reports a robust 36% net profit growth in H1 FY25, despite facing significant hurdles in the US market. Nov 14, 2024
Drug Manufacturers
SMS Pharmaceuticals Ltd (BOM:532815) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Margin Pressures
Despite an 18% revenue increase, SMS Pharmaceuticals Ltd faces challenges with declining gross margins due to rising raw material costs and industry pressures. Nov 14, 2024
Drug Manufacturers
Natco Pharma Ltd (BOM:524816) Q2 FY25 Earnings Call Highlights: Robust Revenue and Profit Growth Amid Market Challenges
Natco Pharma Ltd (BOM:524816) reports a 35.3% revenue increase and 83% profit growth, while navigating future market uncertainties and regulatory challenges. Nov 14, 2024
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers